Glioblastoma Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chim

Glioblastoma Pipeline constitutes 180+ key companies continuously working towards developing 200+ Glioblastoma treatment therapies, analyzes DelveInsight.

Glioblastoma Overview:

Glioblastoma Multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults, accounting for over half of all primary brain tumors and 20% of all intracranial tumors. Despite advances in diagnostics and treatments, its prognosis remains poor. This is due to the tumor's complex genetic and molecular alterations, which disrupt key signaling pathways and drive tumor progression through somatic mutations.

GBM is highly invasive, spreading through brain tissue along nerve fibers, blood vessels, and internal brain linings, making complete surgical removal nearly impossible. It most frequently arises in the subcortical areas of the cerebrum-especially the temporal, parietal, frontal, and occipital lobes-and can also appear in deeper brain regions like the thalamus, cerebellum, and, rarely, the brainstem or spinal cord.

Symptoms are often nonspecific and may include headaches, personality changes, nausea, seizures, cognitive decline, and focal neurological deficits. In rare cases, psychiatric or balance-related symptoms like vertigo can also occur. The tumor's aggressive nature and widespread infiltration make it particularly lethal.

Download our report @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Glioblastoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioblastoma Therapeutics Market.

Key Takeaways from the Glioblastoma Pipeline Report

DelveInsight's Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment.
The FDA approved an Investigational Device Exemption (IDE) application for Alpha DaRT, a novel alpha-radiation cancer therapy. This approval allows for the initiation of a pilot study targeting patients with recurrent glioblastoma, aiming to evaluate the safety and feasibility of this innovative treatment.
The FDA indicated that overall survival data from the GBM-AGILE study could support the standard approval of paxalisib, a PI3K inhibitor, for glioblastoma treatment. This suggests a potential new therapeutic option pending further regulatory review. ​
The FDA approved vorasidenib (brand name Voranigo) for adults and pediatric patients aged 12 years and older with Grade 2 astrocytoma or oligodendroglioma harboring susceptible IDH1 or IDH2 mutations. This marks the first FDA approval of a systemic therapy for this patient population.
Key Glioblastoma companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others are evaluating new drugs for Glioblastoma to improve the treatment landscape.
Promising Glioblastoma pipeline therapies in various stages of development include Enzastaurin, Asunercept, Berubicin, Azeliragon, VXM01, MB-101, and others.

Glioblastoma Pipeline Analysis
The Glioblastoma pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Glioblastoma Market.

Categorizes Glioblastoma therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Glioblastoma drugs under development based on:

Stage of development

Glioblastoma Route of administration

Target receptor

Monotherapy vs. combination therapy

Glioblastoma Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Glioblastoma Licensing agreements

Funding and investment activities supporting future Glioblastoma market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Glioblastoma Emerging Drugs
Enzastaurin: Denovo BioPharma
Asunercept: Apogenix
Berubicin: CNS Pharmaceuticals
Azeliragon: Cantex
VXM01: VAXIMM
MB-101: Mustang Bio

Glioblastoma Companies

Over 180 major companies are currently involved in developing therapies for Glioblastoma. Among these, Denovo has a drug candidate that has progressed to the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 200+ products under different phases of Glioblastoma clinical trials like

Glioblastoma Late stage Therapies (Phase III)
Glioblastoma Mid-stage Therapies (Phase II)
Glioblastoma Early-stage Therapies (Phase I)
Glioblastoma Pre-clinical and Glioblastoma Discovery stage Therapies
Glioblastoma Discontinued & Inactive Therapies

Glioblastoma pipeline report provides the Glioblastoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Glioblastoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Glioblastoma Therapies and Key Glioblastoma Companies: Glioblastoma Clinical Trials and recent advancements https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Glioblastoma Pipeline Therapeutic Assessment
• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage
• Glioblastoma Assessment by Route of Administration
• Glioblastoma Assessment by Molecule Type

Download Glioblastoma Sample report to know in detail about the Glioblastoma treatment market @ Glioblastoma Therapeutic Assessment https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Glioblastoma Current Treatment Patterns
4. Glioblastoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Late-Stage Products (Phase-III)
7. Glioblastoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Discontinued Products
13. Glioblastoma Product Profiles
14. Glioblastoma Key Companies
15. Glioblastoma Key Products
16. Dormant and Discontinued Products
17. Glioblastoma Unmet Needs
18. Glioblastoma Future Perspectives
19. Glioblastoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Glioblastoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.